Lilly Pledges $1.68M in WHO Foundation Pact to Fight Global Obesity

GENEVA, SWITZERLAND – March 06, 2026 – In a significant move to combat one of the world's most pressing health crises, the WHO Foundation today announced a multi-year collaboration with pharmaceutical giant Eli Lilly and Company. The partnership involves a $1.68 million commitment from Lilly through 2029, aimed at bolstering the WHO Foundation's efforts to strengthen health systems for obesity prevention and care, with a sharp focus on resource-limited settings.

The announcement comes as the global scale of the obesity epidemic reaches staggering proportions. According to the World Health Organization, 1 in 8 people worldwide were living with obesity in 2022. The prevalence in adults has more than doubled since 1990, while adolescent obesity has quadrupled. In total, more than 2.5 billion adults are overweight, with 890 million of them living with obesity, a condition that significantly increases the risk of numerous non-communicable diseases, including cardiovascular disease, diabetes, and certain cancers.

A New Alliance Against a Growing Epidemic

This new initiative seeks to move beyond piecemeal programs and instead foster systemic, sustainable change within national health infrastructures. The collaboration aims to equip countries to better diagnose, counsel, and care for people with obesity, ultimately reducing the disease's immense economic and health burden, which the World Obesity Federation projects could surpass $4 trillion annually by 2035.

"Addressing obesity at scale requires more than individual programs. It requires health systems that are prepared to respond across the life course," said Anil Soni, Chief Executive Officer of the WHO Foundation, in a statement. He emphasized that the collaboration will support efforts to "diagnose the gaps and build the necessary architecture" by helping countries integrate evidence-based policies and develop training standards for a health workforce capable of delivering equitable, stigma-free care.

For Eli Lilly, the partnership represents a commitment to tackling the disease on a global public health front. "People living with obesity deserve to receive the care they need to overcome this disease and avoid related health complications," stated Patrik Jonsson, Executive Vice President and President of Lilly International. "By supporting efforts that help health systems recognize and respond to obesity, we aim to slow the global progression of this disease."

The Pharmaceutical Powerhouse Behind the Pledge

The involvement of Eli Lilly is particularly noteworthy given its dominant position in the burgeoning market for obesity treatments. The company's injectable drugs, Zepbound (tirzepatide) and its diabetes-focused counterpart Mounjaro, have become blockbuster therapies, generating billions in revenue. With Zepbound holding a commanding share of new prescriptions in the branded obesity market and a pipeline that includes promising oral candidates like orforglipron, Lilly is a central figure in the pharmacological response to obesity.

This philanthropic investment in public health infrastructure naturally raises questions about the intersection of corporate social responsibility and commercial strategy. Public health analysts note that strengthening health systems in low- and middle-income countries (LMICs) to better recognize and manage obesity could, in the long term, create viable markets for advanced treatments. By helping build the foundational capacity for diagnosis and care, the partnership could pave the way for future access to therapies in regions where they are currently unavailable.

Such public-private partnerships are increasingly common in global health but are often scrutinized for potential conflicts of interest. The key, according to ethics experts, lies in robust transparency and ensuring the public health agenda is not unduly influenced by commercial interests. This collaboration will be closely watched as a model for how corporate capital can be leveraged to build health equity, provided it remains aligned with the WHO's broader, evidence-based public health goals, such as its Acceleration Plan to Stop Obesity.

Targeting the Front Lines in Resource-Limited Regions

The partnership's focus on resource-limited settings addresses a critical and often-overlooked aspect of the obesity crisis. While historically associated with high-income nations, the most rapid growth in obesity rates is now occurring in LMICs. These countries often face a "double burden of malnutrition," where undernutrition and obesity coexist, sometimes within the same community or household.

Health systems in these regions are frequently ill-equipped to handle the rise of chronic, non-communicable diseases. Key challenges include a lack of training for healthcare providers on obesity management, pervasive weight-related stigma that discourages patients from seeking care, and a failure to integrate obesity services into primary healthcare. Furthermore, poor access to healthy foods and the proliferation of inexpensive, ultra-processed products create an environment where obesity thrives.

This initiative aims to address these systemic weaknesses directly. By funding assessments to identify care gaps and supporting the development of integrated care pathways, the collaboration intends to help countries build the capacity to manage obesity as the chronic disease it is. This aligns with the WHO's 2023 Health Service Delivery Framework, which calls for integrating obesity prevention and management into universal health coverage to ensure a chronic care approach across the life course.

A Paradigm Shift: From Blame to Systemic Care

Underpinning this collaboration is a fundamental shift in the global understanding of obesity. For decades, the narrative was dominated by notions of individual responsibility and willpower. Today, the medical and public health communities increasingly recognize obesity as a complex, multifactorial chronic disease influenced by genetics, environment, and socioeconomic factors.

The emphasis on building systems for "equitable, stigma-free care" reflects this modern paradigm. It acknowledges that effective management requires a supportive healthcare environment where patients are treated with dignity and provided with comprehensive, evidence-based options. This includes early diagnosis, nutritional counseling, and, where appropriate, access to medical treatments.

While advanced anti-obesity medications like Lilly's own GLP-1 agonists are transforming care in wealthier nations, their cost and the logistics of their delivery present formidable barriers in LMICs. By focusing first on strengthening the underlying health system, this partnership takes a crucial step toward creating an environment where future innovations, including more affordable therapeutics, can be integrated effectively and equitably. The long-term vision is a world where a person's geographic location and economic status do not determine their ability to receive care for this complex global disease.